Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA.

Aigbogun, Myrlene S; Liu, Sizhu; Kamat, Siddhesh A; Sapin, Christophe; Duhig, Amy M; Citrome, Leslie

Aigbogun, Myrlene S; Liu, Sizhu; Kamat, Siddhesh A; Sapin, Christophe; Duhig, Amy M; Citrome, Leslie.

Afiliação

Aigbogun MS; Health Economics and Outcomes Research, Otsuka Pharmaceutical Development and Commercialization, Inc, Princeton, NJ, USA, Myrlene.Sanon@gmail.com.
Liu S; Global Health Economics and Outcomes Research, Xcenda, Palm Harbor, FL, USA.
Kamat SA; Health Economics and Outcomes Research, Otsuka Pharmaceutical Development and Commercialization, Inc, Princeton, NJ, USA, Myrlene.Sanon@gmail.com.
Sapin C; Global Analytics, Lundbeck, Paris, France.
Duhig AM; Global Health Economics and Outcomes Research, Xcenda, Palm Harbor, FL, USA.
Citrome L; Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA.

Clinicoecon Outcomes Res ; 10: 443-456, 2018.

Article em En | MEDLINE | ID: mdl-30147350

Palavras-chave

brexpiprazole; cost-benefit; cost-effectiveness; event avoided; hospitalization avoided; indirect analysis; relapse prevention; schizophrenia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google